Biopharmaceutical company DiscGenics, Inc. has hired Jeff Poole as its first Chief Financial Officer. Mr. Poole will report to DiscGenics Chief Executive Officer and Chairman of the Board of Directors Flagg Flanagan, and oversee all of the company’s finances.
"The addition of Jeff to the DiscGenics executive team represents a huge opportunity for us as we move through our final clinical stages and evaluate various financing and commercial opportunities going forward in the U.S. and Japan," said Mr. Flanagan.
Mr. Poole comes to DiscGenics from Medtronic Spine and Biologics, where, as Vice President of Finance, he was responsible for overseeing more than $2.5 billion in annual revenue. He has more than 13 years of financial leadership experience in the medical devices industry.
"I am thrilled to be joining DiscGenics because I truly believe its innovative regenerative therapy addresses an unmet clinical need and could significantly alter the definition of Standard of Care for patients suffering from spinal disc degeneration,” said Mr. Poole. “I look forward to working with Flagg and the entire DiscGenics team to help realize the full clinical and commercial potential of IDCT for the millions of patients suffering from chronic low back pain worldwide."